Research and surveillance activities include surveillance of vaccine preventable diseases, vaccination coverage and adverse events, vaccine safety and program evaluations and social research. NCIRS also provides technical support for the Australian Technical Advisory Group on Immunisation, including production of The Australian Immunisation Handbook.
Vaccine Safety Net Member
Our website meets the criteria for credibility and content as defined by the Global Advisory Committee on Vaccine Safety.
We acknowledge that the National Centre for Immunisation Research & Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn.
* ‘Indigenous’ is used on these pages to incorporate all Aboriginal and Torres Strait Islander peoples.
A study has found there is scope to reduce child deaths, particularly from influenza, meningococcal B and pertussis. Maternal vaccination along with increased uptake of vaccination in children (with and without underlying medical conditions), particularly for influenza, could reduce residual child deaths.
The study, conducted by the NCIRS and published in the Journal of Paediatrics and Child Health, found 23 deaths still occurred between 2005 and 2014 in NSW that could have been prevented by vaccines that were available at the time, with influenza (12 deaths) and meningococcal disease (5 deaths) most common.
Australia’s novel, active surveillance system, AusVaxSafety, monitors the post-market safety of vaccines in near real time. This paper analysed cumulative surveillance data for children aged 6 months to 4 years who received seasonal influenza vaccine in 2015 and/or 2016 to determine: adverse event following immunisation (AEFI) rates by vaccine brand, age and concomitant vaccine administration. 7402 children were included in the analysis and no safety signals or excess of adverse events were detected.